Treatment of Kienbock's disease with capitohamate arthrodesis: pain relief with minimal morbidity.
Despite the large number of procedures available for treatment of Kienbock's disease, no single method has emerged as being clearly superior. Ultimately, the goal of treatment must be the relief of pain and maintaining wrist range of motion. The authors' experience with 45 consecutive wrists that had undergone capitohamate fusion for treatment of Lichtman's stage 1, 2, or 3 Kienbock's disease is presented. Average follow-up was 32 months (range, 4 to 107 months). All arthrodeses healed with an average time to fusion of 1.9 months. Postoperatively, 93 percent of patients had either no pain or less pain than they had preoperatively, with preservation of wrist range of motion and improved grip strength (52 percent of normal preoperatively to 72 percent of normal postoperatively). The authors conclude that capitohamate arthrodesis relieves pain in 93 percent of patients with stage 1, 2, or 3 Kienbock's disease and is an effective treatment for this disease.
Oishi
Scott N
SN
Department of Hand Surgery, Texas Scottish Rite Hospital, Dallas, Texas 75219, USA. scottoishi@aol.com
Muzaffar
Arshad R
AR
Carter
Peter R
PR
D000293:Adolescent; D000328:Adult; D001174:Arthrodesis / Q000379:methods*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010007:Osteochondritis / Q000503:physiopathology / Q000601:surgery*; D010146:Pain; D016059:Range of Motion, Articular; D016896:Treatment Outcome; D014955:Wrist Joint / Q000601:surgery*